Clinical Trial

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Protocol Amendment History 6 changes
notable Trial sites expanded: 80 -> 83 locations 2026-07-29
notable Trial sites expanded: 77 -> 80 locations 2026-07-08
notable Trial sites expanded: 73 -> 77 locations 2026-06-24
notable Trial sites expanded: 68 -> 72 locations 2026-05-21
notable Trial sites expanded: 64 -> 68 locations 2026-05-07
notable Trial sites expanded: 58 -> 64 locations 2026-04-01
Trial Details
NCT Number NCT07214571
Lead Sponsor Shionogi
Conditions Respiratory Syncytial Virus Infections
Enrollment 192 participants
Start Date 2025-12-11
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11